Overview

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Daiichi Sankyo
Collaborator:
Merck Sharp & Dohme LLC
Treatments:
Doxorubicin
Gemcitabine
Liposomal doxorubicin
Paclitaxel
Topotecan